Last updated: 2026-09-16 10:32:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Elicio Therapeutics, Inc. (ELTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.88, with a market capitalisation of $52.56M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.88 to $16.00. This page covers its latest market performance, valuation, price trends and company information.
$52.56M | |
$1.99 | |
$24.39 | |
$1.88 | |
$1.99 | |
31.05K | |
1.62M | |
-- | |
$16.00 | |
$1.88 | |
-- | |
-- |
Elicio Therapeutics, Inc. (ELTX) is trading at $1.88 in pre-market trading as of 2026-09-16 09:38:00, down 5.48% ($0.11) from the previous close of $1.99
Pre-market trading shows how investors are pricing ELTX before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Elicio Therapeutics, Inc. (ELTX) moved from $2.41 to $1.88, representing a decline of 21.95% ($0.53).
The stock traded between $1.88 and $2.50 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 395.94 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.0%
ELTX is currently trading at $1.88, placing it 0.0% of the way from its 52-week low of $1.88 to its 52-week high of $16.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 33 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Elicio Therapeutics, Inc. (ELTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.